Metagenomi, Inc. financial data

Symbol
MGX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5959 Horton Street, 7 Th Floor, Emeryville, CA
Fiscal year end
December 31
Former names
Metagenomi Technologies, LLC (to 1/18/2024)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 506 %
Debt-to-equity 76.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.4M shares
Common Stock, Shares, Outstanding 37.4M shares
Common Stock, Value, Issued 4K USD
Weighted Average Number of Shares Outstanding, Basic 36.8M shares +980%
Weighted Average Number of Shares Outstanding, Diluted 36.8M shares +980%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 11.5M USD -6.87%
Research and Development Expense 26.3M USD -2.17%
General and Administrative Expense 7.64M USD -3.54%
Operating Income (Loss) -22.4M USD +0.05%
Nonoperating Income (Expense) 1.5M USD -60.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.9M USD -12.2%
Income Tax Expense (Benefit) -2.11M USD -275%
Net Income (Loss) Attributable to Parent -18.8M USD +5.28%
Earnings Per Share, Basic -0.51 USD/shares +91.2%
Earnings Per Share, Diluted -0.51 USD/shares +91.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.1M USD -75.4%
Cash, Cash Equivalents, and Short-term Investments 275M USD
Assets, Current 282M USD
Property, Plant and Equipment, Net 19.7M USD
Operating Lease, Right-of-Use Asset 40.2M USD
Other Assets, Noncurrent 320K USD
Assets 358M USD
Accounts Payable, Current 3.1M USD
Contract with Customer, Liability, Current 29.1M USD
Liabilities, Current 45.7M USD
Contract with Customer, Liability, Noncurrent 12.4M USD
Operating Lease, Liability, Noncurrent 41.4M USD
Other Liabilities, Noncurrent 3.08M USD
Liabilities 103M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.64M USD
Retained Earnings (Accumulated Deficit) -200M USD
Stockholders' Equity Attributable to Parent 256M USD
Liabilities and Equity 358M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.9M USD -42.2%
Net Cash Provided by (Used in) Financing Activities 86.5M USD +1915%
Net Cash Provided by (Used in) Investing Activities -94.7M USD -31.4%
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 37.4M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -38M USD +57.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.4M USD -71.7%
Depreciation 1.27M USD +51.4%
Payments to Acquire Property, Plant, and Equipment 915K USD -65.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.9M USD +14.6%
Operating Lease, Liability, Current 4.7M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 454M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 15.8M USD -1.38%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares